Propanc Biopharma Inc. (PPCB) - Debt to Equity

Propanc Biopharma Inc (PPCB) is actively developing innovative methods to combat metastasis in solid tumors. The business relies on the creation of pancreatic proenzymes that target cancer stem cells. This chart confirms a market price reflecting a debt-to-equity ratio of 0.05. However, the R&D stage carries risks of high cash burn, lack of profitability, and competition from pharma behemoths.

This indicator measures the proportion of debt obligations relative to equity, determining the degree of financial leverage and the business's dependence on external financing. Since Propanc Biopharma Inc (PPCB) utilizes outsourcing for production and testing, the total debt-to-equity ratio reflects the efficiency of its capital expenditure minimization strategy, allowing investors to assess the company's stability without the ownership of costly assets.